NGS-based RNA-sequencing Market To Reach $10.05 Billion By 2030

April 2025 | Report Format: Electronic (PDF)

NGS-based RNA-sequencing Market Growth & Trends

The global NGS-based RNA-sequencing market size is expected to reach USD 10.05 billion by 2030 and is anticipated to grow at a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to rising demand for precision medicine, advancements in sequencing technologies, and increasing applications in diagnostics, drug discovery, and disease research. Expanding bioinformatics capabilities and declining sequencing costs further support widespread market adoption.

The COVID-19 pandemic has accelerated the adoption of NGS-based RNA-sequencing owing to its critical role in understanding viral mutations, host response, and pathogen transcriptomics. The urgent need for advanced genomic tools in vaccine and therapeutic development highlighted the value of RNA-sequencing, driving rapid integration into research and public health efforts. This shift has reinforced its importance in infectious disease monitoring and preparedness.

In addition, advancements in high-throughput sequencing technologies have significantly enhanced the speed, accuracy, and scalability of RNA-sequencing. These innovations enable more comprehensive transcriptome profiling, reduce turnaround times, and lower costs, making NGS-based RNA sequencing more accessible for both research and clinical applications.

However, high initial costs associated with sequencing platforms and infrastructure, and ethical concerns surrounding genomic data usage are expected to hamper market growth. These challenges may limit adoption, particularly in resource-constrained settings and regions with stringent data privacy regulations.


key Request a free sample copy or view report summary: NGS-based RNA-sequencing Market Report


NGS-based RNA-sequencing Market Report Highlights

  • Based on product and service, the consumables segment dominated with the largest revenue share of 58.12% in 2024, due to continuous advancements in reagent chemistry and the growing demand for quality, efficient sequencing kits. However, services are expected to grow at the fastest CAGR over the forecast period.

  • Based on workflow, the sequencing segment held the largest market share in 2024, driven by increased adoption of advanced platforms offering faster turnaround and cost-effective processing. On the other hand, the data analysis segment is anticipated to witness the fastest CAGR of 18.49% over the forecast period.

  • Based on application, the drug discovery & development segment holds the largest revenue share for application in 2024. This is attributed to the growing use of RNA-sequencing in identifying novel targets and accelerating therapeutic development. However, the clinical diagnostics segment is projected to grow at the highest CAGR over the forecast period.

  • Based on end use, the pharmaceutical & biotechnology companies segment held the largest share in 2024. The growth is due to increased adoption of RNA-sequencing for biomarker discovery, clinical research, and personalized drug development. On the other hand, the hospitals & clinics segment is expected to register the fastest growth rate during the projected period.

  • North America dominated the NGS-based RNA-sequencing market owing to factors such as advanced healthcare infrastructure, strong research funding, and high adoption of precision medicine and genomic technologies. Asia Pacific is expected to grow at the fastest CAGR during the forecast period.

NGS-based RNA-sequencing Market Segmentation

Grand view research has segmented the NGS-based RNA-sequencing market based on product & services, workflow, application, end use, and region:

NGS-based RNA-sequencing  Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

    • Extraction & Purification Kits

    • Library Preparation Kits

    • Sequencing Reagents & Flow Cells

    • Others

  • Instruments

  • Service           

    • RNA-sequencing

    • Bioinformatics & Data Analysis

NGS-based RNA-sequencing  Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-sequencing

  • Sequencing

  • Data Analysis

NGS-based RNA-sequencing  Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Drug Discovery & Development

    • Oncology

    • Infectious Diseases

    • Others

  • Clinical Diagnostics

  • Others

NGS-based RNA-sequencing  End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Academic & Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & Clinics

  • Others

NGS-based RNA-sequencing  Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

List of Key Players in theNGS-based RNA-sequencing Market

  • Illumina, Inc.

  • Thermo Fisher Scientific Inc.

  • Merck KGaA

  • QIAGEN N.V.

  • Pacific Biosciences of California, Inc.

  • Oxford Nanopore Technologies Ltd.

  • Agilent Technologies, Inc.

  • BGI Group

  • Roche Holding AG

  • Revvity, Inc.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.

Request Customization